Mylan, MarkMonitor, Coca-Cola: Intellectual Property
This article is for subscribers only.
Mylan Inc., the generic-drug maker with an exclusive agreement to sell a copy of GlaxoSmithKline Plc’s Paxil CR, lost its bid for a preliminary court order blocking Apotex Inc. from also selling the antidepressant medicine.
“We can confirm that Mylan’s application for a preliminary injunction was denied, and we are pleased with the result,” said Sarah Alspach, a spokeswoman for GlaxoSmithKline.